In neurodegenerative diseases, TMAO penetrates the BBB, impairing synaptic plasticity through PERK activation or mTOR pathway inhibition (Zhou et al., 2023), while promoting Aβ and tau protein aggregation in Alzheimer’s and Parkinson’s disease progression. The gene discussed is MAPT; the disease is Parkinson disease.